When defining harmonization, the writing committee followed the NQF Guidance for Measure Harmonization report, which states measure harmonization should be con- sidered when measures are intended to address either the same measure focus the target process, condition, event, outcome (eg, numerator) or the same target pop- ulation (eg, denominator). 23 The enhancing performance and quality measures are intended to promote the wide- spread application in clinical practice of the current recom- mendations from the 2017 Hypertension Clinical Practice to improve care and outcomes for all patients with HBP, including those with ACC/AHA stage 1 HBP and elevated BP. The writing committee acknowledges that adding new performance measures may not be initially feasible in the current regulatory environment, in which many healthcare entities already have a high burden to collect and report existing quality measures. Nonetheless, it is imperative that national quality improvement efforts urgently incorporate high-quality, evidence-based recom- mendations into practice, especially given the recent lack of significant progress in controlling HBP with national measures in current use by CMS, NCQA, state Medicaid agencies, NQF, and other entities (Figure 1).6 The writing committee reviewed clinical practice guidelines and other clinical guidance documents recently published by other entities, in addition to ACC/ AHA documents. The writing committee also exam- ined available information on gaps in care to address which new measures might be appropriate as perfor- mance measures or quality measures for this measure set update, based on the attributes for performance measures outlined in Table 7. 3. AHA/ACC HBP MEASURE SET PERFORMANCE MEASURES 3.1. 